Evidence map›Paper›PMID 31080874›Full record

ArticleInternational journal of cardiology. Heart & vasculature2019

The tertiary hospital laboratory; a novel avenue of opportunistic screening of familial hypercholesterolemia.

Sam Mirzaee, Kay W Choy, James C G Doery, Sarah Zaman, James D Cameron, Arthur Nasis

Open access · goldAbstract read
In one paragraph

Article in International journal of cardiology. Heart & vasculature, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Sam MirzaeeMonash Cardiovascular Research Centre, MonashHEART, Monash Health, Monash University, Melbourne, Australia.
Kay W ChoyMonash Health Pathology, Monash Health, Monash University, Melbourne, Australia.
James C G DoeryMonash Health Pathology, Monash Health, Monash University, Melbourne, Australia.
Sarah ZamanMonash Cardiovascular Research Centre, MonashHEART, Monash Health, Monash University, Melbourne, Australia.
James D CameronMonash Cardiovascular Research Centre, MonashHEART, Monash Health, Monash University, Melbourne, Australia.
Arthur NasisMonash Cardiovascular Research Centre, MonashHEART, Monash Health, Monash University, Melbourne, Australia.
Monash Health · AUMonash University · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundFamilial hypercholesterolemia (FH) is a common monogenic hereditary lipid disorder characterised by increased serum low-density lipoprotein cholesterol (LDL-cholesterol) concentrations and high risk of premature atherosclerotic cardiovascular disease. The prevalence of FH identified in a tertiary hospital laboratory was investigated by performing an opportunistic screen for index cases.

methodsThe prevalence of likely FH based on LDL-cholesterol thresholds >4.9 mmol/L as employed by the Dutch Lipid Clinic Network Criteria (DLCNC) score was evaluated retrospectively in a single tertiary hospital laboratory over a six-month period (July to December 2016).

results4943 lipid profiles screened, 106 patients (mean age 53.2 ± 12.9 and 41% male) had LDL-cholesterol of >4.9 mmol/L after exclusion of 5 patients (0.1%) with secondary causes. Possible (n = 90) and probable/definite (n = 16) FH according to DLCNC score was seen in 1.8% and 0.4% of the overall screened population, respectively.

conclusionsPoint prevalence of screening for FH in patients undergoing lipid profile testing in a tertiary hospital laboratory was comparable with prevalence of FH in general population (based on 1 in 200-250). This supports the benefit of establishing an efficient "alert system" in conjunction with a trigger "reflex testing" to facilitate further formal FH scoring and exclusion of possible secondary causes of hyperlipidemia in potential index FH.

Indexed as

AHA, American Heart AssociationAPO-B, Apolipoprotein-BASCVD, Atherosclerotic cardiovascular diseaseCAD, Coronary artery diseaseDLCNC, Dutch Lipid Clinic Network CriteriaFamilial hypercholesterolemiaFHFH, Familial hypercholesterolemiaHDL-C, High density lipoprotein cholesterolHIV, Human immunodeficiency virusLDL-cholesterol, Low-density lipoprotein cholesterolLDL-R, Low density lipoprotein receptorOpportunistic screeningPCSK-9, Proprotein convertase subtilisin/kexin type-9Tertiary hospital laboratory

Identifiers

PMID31080874
PMCPMC6503163
OpenAlexW2943723795

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.